Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR) Files An 8-K Regulation FD Disclosure

Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

On July 13, 2017, Citius Pharmaceuticals, Inc. (the “Company”) posted company presentation materials on its website. A copy of the Company’s presentation materials is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.


Citius Pharmaceuticals, Inc. Exhibit

To view the full exhibit click here

About Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR)

Citius Pharmaceuticals, Inc., formerly Trail One, Inc., is a pharmaceutical company engaged in developing and commercializing therapeutic products. The Company focuses on developing formulations to manage the delivery and compliance of approved drugs. The Company offers Suprenza, an orally disintegrating tablet and an obesity drug that can be administered with water or dissolved on tongue. The Company also focuses on development of its product candidate, Hydrocortisone-Lidocaine Cream, which is in Phase II study. Its Hydrocortisone-Lidocaine Cream is used to provide anti-inflammatory and anesthetic relief to persons suffering from grade I and II hemorrhoids. Citius Pharmaceuticals, LLC is its subsidiary. The Company has not generated any revenues.

An ad to help with our costs